Blood donor screening in the Netherlands: Universal anti‐HBc screening in combination with HBV nucleic acid amplification testing may allow discontinuation of hepatitis B virus antigen testing

Blood donor screening in the Netherlands: Universal anti‐HBc screening in combination with HBV nucleic acid amplification testing may allow discontinuation of hepatitis B virus antigen testing

Background In the Netherlands, blood donor screening for hepatitis B virus (HBV) consists of HBsAg screening since the 1970s, HBV DNA minipool testing (MP‐NAT) since 2008, and anti‐HBc screening since 2011. Anti‐HBc reactivity causes deferral only if anti‐HBs titers are

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transfusion (Philadelphia, Pa.) Pa.), 2021-07, Vol.61 (7), p.2116-2124
Hauptverfasser: Laar, Thijs J., Hogema, Boris M., Molenaar‐de Backer, Marijke W., Marijt‐van der Kreek, Tanneke, Zaaijer, Hans L.
Format: Artikel
Sprache:eng
Schlagworte:
Antigens
Blood
Blood & organ donations
Deoxyribonucleic acid
DNA
Health risks
Hepatitis
Hepatitis B
Hepatitis B surface antigen
Infections
infectious disease testing
Markers
Nucleic acids
Screening
transfusion transmitted disease—hepatitis
Viruses
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background In the Netherlands, blood donor screening for hepatitis B virus (HBV) consists of HBsAg screening since the 1970s, HBV DNA minipool testing (MP‐NAT) since 2008, and anti‐HBc screening since 2011. Anti‐HBc reactivity causes deferral only if anti‐HBs titers are
ISSN:0041-1132
1537-2995
DOI:10.1111/trf.16420